- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05679544
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs (PAH-ProMetGen)
Biological Signatures (Proteomics, Metabolomics and Genotoxicity) Associated With Occupational Exposure to PAH Mixtures and Relation With Exposure Biomarkers: Support for the Derivation of Biological Limit Values
This research project aims at better understanding the early biological effects resulting from occupational exposure to complex Polycyclic Aromatic Hydrocarbon (PAH) mixtures.
Current biomarkers used as part of biomonitoring campaigns are biomarkers of exposure, not numerous and poorly related to health effects.
The aim of this study is thus to improve our understanding of biological consequences of such exposures, both in terms of proteins deregulation, metabolism deregulation and genotoxicity.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PAHs are ubiquitous pollutants inducing several diseases, among which cancer is the most significant endpoint, with increased incidences of lung, skin, and bladder cancers. PAHs induce genotoxic effects (sister chromatids exchange, micronuclei, DNA damage) but require metabolic activation in humans as indirect-acting carcinogens. Thus, the knowledge of metabolic pathways involved following PAH exposure is critical for understanding and preventing cancer risks. Besides, exposure to PAHs is assumed to induce other adverse health effects (diabetes, inflammation, infertility, cardiovascular disease). Unfortunately, early disease-related biomarkers are still largely unknown and our comprehension about the mechanisms involved is still limited. The rare existing biological limit values either refer to not carcinogenic PAH (pyrene) or detoxification pathways (3-OHBaP for BaP), although new biomarkers reflecting the genotoxic pathway of BaP (TetraolBaP) are now available. There is thus a need for identifying more relevant biomarkers of exposure / effect, and for a better understanding of the biological consequences resulting from PAH exposures as well as the associated metabolic pathways involved.
The objectives of the project are :
- To better understand and characterize molecular, metabolic and genotoxic impacts resulting from exposure to PAHs and to link such impacts with biological levels of various PAH metabolites,
- To study the influence of BaP metabolism (genotoxic versus detoxication pathway) on the differential expression of metabolites / proteins and on genotoxicity endpoints in order to get relevant data for deriving new biological limit values,
- To elucidate the associations between omics deregulations due to PAH exposures and activated metabolic pathways, in order to define candidate effect biomarkers for human biomonitoring.
The originalities of the project are the following. First, this is a human study performed in real occupational settings on workers exposed to representative PAH mixtures. It is a multidisciplinary approach simultaneously combining up-to-date biomonitoring, omics and cytogenetics analyses, that will give insight into a comprehensive view of metabolic reactions and protein expressions following occupational exposure to PAH mixtures, and allow the identification of the biological processes involved. Carcinogenic BaP metabolites (Tetraol-BaP and 3-OHBaP) will be simultaneously analyzed in order to compare the two main metabolic pathways of BaP.
The main steps of the projects will be :
- Recruitment of 100 workers differentially exposed to PAH mixtures sampled across two time periods (after weeks of exposure and following 3 weeks without occupational exposure),
- Recording of relevant data (work characteristics, jobs / tasks, working experience, number of years of exposure, smoking habits, nutritional intake, co-morbidity),
- Toxicological analyses (LC-Fluorescence and GC-MS-MS) of urinary metabolites of several gaseous and particulate PAHs (Naphtalene, Fluorene, Phenanthrene, Pyrene, BaP, BeP, Chrysene, Benzo(b)Fluoranthene, Benzo(k)Fluoranthene, Benzo(a)Anthracene),
- Proteomics analyses on blood samples through an enrichment approach for a bottom-up label free quantitative proteomic analysis based LC-HR-MS. Deregulated proteins (DEP) will be identified and the associated protein signature. A gene ontology (GO) analysis will define the groups of biological processes involved,
- Untargeted Metabolomics analyses on blood samples in UHPLC-HR-MS, with unsupervised statistical analyses (Principal Component Analysis, Logistic Regressions), identification of relevant metabolites by their comparison to the Human Metabolome database, and advanced molecular networking / spectral library search of LC-MSMS data,
- Micronuclei (MN) in buccal cells through the harvesting of buccal cells using a cytobrush, transfer to the lab in a buffer, fixing and staining, automatic counting under fluorescent light.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Renaud PERSOONS, PhD, Pharm D
- Phone Number: 00 33 4 76 76 51 78
- Email: RPersoons@chu-grenoble.fr
Study Contact Backup
- Name: Christine DEMEILLIERS, PhD
- Phone Number: 00 33 4 76 63 75 01
- Email: christine.demeilliers@univ-grenoble-alpes.fr
Study Locations
-
-
-
Grenoble, France, 38043
- Recruiting
- CHU Grenoble Alpes
-
Contact:
- Renaud Persoons
- Phone Number: 04 76 76 51 78
- Email: RPersoons@chu-grenoble.fr
-
Contact:
- Christine Demeilliers
- Phone Number: 04 76 63 75 01
- Email: christine.demeilliers@univ-grenoble-alpes.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects ages 18 years or more
- Subjects occupationally exposed to PAHs since more than 3 months
- Having signed the informed consent
- recruited by the occupational health service
Exclusion Criteria:
- Obesity (BMI>30)
- Subjects suffering cancers or metabolic diseases (diabetes, dyslipidemia, amino-acid diseases, renal or hepatic impairment) at the onset of the study.
- Subjects taking medications related to the above diseases at the onset of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subjects occupationally exposed to PAHs
|
Biological samples collected in period of exposure and after holidays
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Deregulation of blood proteins expression due to exposure to PAHs
Time Frame: up to 6 months between both periods of study
|
Number of proteins up or down regulated in period of exposure versus after holidays
|
up to 6 months between both periods of study
|
Deregulation of blood metabolites expression due to exposure to PAHs
Time Frame: up to 6 months between both periods of study
|
Number of metabolites up or down regulated in period of exposure versus after holidays
|
up to 6 months between both periods of study
|
Frequency of micronuclei measured due to exposure to PAHs
Time Frame: up to 6 months between both periods of study
|
Frequency of cells containing micronuclei in period of exposure versus after holidays
|
up to 6 months between both periods of study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Renaud PERSOONS, University Hospital, Grenoble
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 38RC22.0219
- 2022-A01590-43 (Other Identifier: IDRCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Disturbance
-
The Swedish School of Sport and Health SciencesActive, not recruiting
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of TorontoCanadian Institutes of Health Research (CIHR)RecruitingSedentary Behavior | Metabolic DisturbanceCanada
-
Northumbria UniversityCompletedMetabolic Disturbance | Dietary ExposureUnited Kingdom
-
Appalachian State UniversityRecruitingGastrointestinal Dysfunction | Metabolic DisturbanceUnited States
-
University of TorontoWomen's College HospitalCompleted
-
University of TorontoCompletedMetabolic DisturbanceCanada
-
Northumbria UniversityUnknownMetabolic Disturbance | Dietary ExposureUnited Kingdom
-
University of NottinghamCompletedObesity | Metabolic DisturbanceUnited Kingdom
Clinical Trials on Characterization of early biological effects following exposure to PAHs
-
Bispebjerg HospitalRigshospitalet, DenmarkUnknownPediatric | Neonatal | Excipient Exposure
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Harvard UniversityYale UniversityCompletedMalnutrition | Dysentery | Social Transmission of Health BehaviorsUnited States
-
Ricard MarcosHospital Universitario Virgen de la Arrixaca; Instituto Murciano de Investigación...RecruitingChronic Kidney Diseases | Microplastics | Nanoplastics | Genotoxic DamageSpain
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
University of California, Los AngelesCompleted
-
University of California, Los AngelesCompleted
-
University Hospital, MontpellierUniversity Hospital, BordeauxRecruitingCryptorchidismFrance
-
University of ZurichMerck Sharp & Dohme LLCCompletedUlcerative Colitis | Flare Up, SymptomSwitzerland
-
University of ZurichUnknownUlcerative Colitis | Flare Up, SymptomSwitzerland